Effectiveness of a short-term group psychotherapy program on endocrine and immune function in breast cancer patients: An exploratory study

Journal of Psychosomatic Research

Volumn 42, Issue 5, 1997, Pages 453-466

  Van Der Pompe, Gieta ^a,b   Duivenvoorden, Hugo J ^a   Antoni, Michael H ^a   Visser, Adriaan ^a   Heijnen, Cobi J ^a  

^a HELEN DOWLING INSTITUTE   (Netherlands)

^b UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

Breast cancer; Endocrines; Group psychotherapy program; Immune function

Indexed keywords

HYDROCORTISONE; POKEWEED MITOGEN; PROLACTIN;

ADULT; AGED; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CELL COUNT; CELL PROLIFERATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ENDOCRINE FUNCTION; FEMALE; GROUP THERAPY; HEALTH PROGRAM; HOSPITAL ADMISSION; HUMAN; HYDROCORTISONE BLOOD LEVEL; IMMUNE SYSTEM; KILLER CELL; LYMPHOCYTE COUNT; PROLACTIN BLOOD LEVEL;

EID: 0030966507     PISSN: 00223999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-3999(96)00393-5     Document Type: Article

References (40)

1. Andersen B. Psychological interventions for cancer patients to enhance the quality of life. J Consult Clin Psychol 1992;66:552-568.
2. Trijsburg RW, Knippenberg FC van, Rijpma SE. Effects of psychological treatment on cancer patients: a critical review. Psychosom Med 1992;54:489-517.
3. Mulder CL. Psycho-immunology and HIV infection. Biopsychosocial determinants of distress, immunological parameters, and disease progression in homosexual men infected with human immunodeficiency virus - 1. Doctoral dissertation, Rotterdam, The Netherlands 1994.
4. van der Pompe G, Antoni MH, Visser A, Garssen B. Adjustment to breast cancer: The psychobiological effects of psychosocial interventions. Pat Educ Coun 1996;28:209-219.
5. Fawzy FI, Kemeny NW, Fawzy N, Elashoff R. A structured psychiatric intervention for cancer patients. II. Changes over time in immunological measures. Arch Gen Psychiatry 1990;47:729-735.
6. Schedlowski M, Jung C, Schimanski G, Tewes U, Schmoll HJ. Effects of behavioral intervention on plasma cortisol and lymphocytes in breast cancer patients: an exploratory study. Psychooncology 1994;3:181-187.
7. Contreras Ortiz O, Stoliar A: Immunological changes in human breast cancer. Eur J Gynaecol Oncol 1986;6:502-514.
8. Burford-Mason A, Gyte GM, Watkins SM. Phytohaemagglutinin responsiveness of peripheral lymphocytes and survival in patients with primary breast cancer. Breast Cancer Res Treat 1989;13: 243-250.
9. Mohanty I, Nayak M, Nanda BK. Cell mediated immune status in breast carcinoma. Indian J Pathol Microbiol 1991;34:1-6.
10. Drafta DS, Stroe E, Schindler EE, Toedosiu T, Gozariu L, Drafta D. Adrenal function in early and metastatic breast cancer patients. Endocrinology 1981;19:115-121.
11. Hays JH, O'Brian JT: Endocrine and metabolic function in patients with neoplastic disease. In: Herberman RB, ed. Influence of the host on tumor development. Dordrecht: Kluwer 1989.
12. van der Pompe G, Antoni MH, Heijnen CJ. Elevated basal cortisol levels and attenuated ACTH and cortisol responses to a behavioral challenge in women with metastatic breast cancer. Psychoneuroendocrinology 1996;21:361-374.
13. van der Pompe G, Antoni MH, Heijnen CJ. The effects of surgical stress and psychological stress on the immune function of operative cancer patients. Psychol Health (in press).
14. Yalom I. Existential psychotherapy. New York, Basic Books 1983.
15. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry 1961;4:561-571.
16. Bouman TK, Luteijn F, Albersnagel FA, Ploeg FA. Enige ervaringen met de Beck Depression Inventory (BDI). Gedrag 1985;13:13-24.
17. Spielberger CD. Test manual for the State-Trait Anxiety Inventory - STAI Form Y. Palo Alto, California: Consulting Psychologist Press 1980.
18. van der Ploeg HM, Defares PD, Spielberger CD. Handleiding bij Zelfbeoordelings-vragenlijst (ZBV). Lisse: Swets & Zeitlinger 1980.
19. McNair DM, Lorr M, Droppleman LF. Profile of mood states. San Diego, California: Educational and Industrial Testing Service, 1971.
20. Wald FDM, Mellenberg GJ. De verkorte versie van de Nederlandse vertaling van de Profile of Mood States (POMS). Ned Tijdschr Psychol 1990;45:86-99.
21. Ottenhof PC, Morales A, Baines MG. Quantitation of a whole blood assay for human natural killer cell activity. J Immunol Meth 1981;425:305-318.
22. Baron GC, Klimas NG, Fischl MA, Fletcher MA. Decreased natural cell-mediated cytotoxicity per effector cell in acquired immunodeficiency syndrome. Diagn-Immunol 1985;3:197-204.
23. Bloemena E, Roos MTL, Van Heijst JLAM, Vossen JMJJ, Schellekens PTA. Whole-blood lymphocyte cultures. J Immunol Meth 1989;122:161-167.
24. Harris B, Cook N, Warner N. Anxiety and the demamethasone suppression test monitored with saliva. Biol Psychiatry 1988;23:698-704.
25. Jöreskog KG, Sörbon D. Statistical models and methods for analysis of longitudinal data. In: Aigner DJ, Goldberger AS, eds. Latent variables in socioeconomic models. Amsterdam: North Holland, 1977.
26. Jöreskog KG. Testing statistical equation models. In: Bollen KA, Lang JS, eds. Testing statistical equation models. London: Sage, 1993.
27. Glantz SA, Slinker BK. Primer of applied regression and analysis of variance. New York: McGraw-Hill 1990.
28. Herberman RB, Wiltrout R, Gorelik E. Immune responses to metastases. Boca Raton, Florida: CRC Press, 1987.
29. Levy SM, Herberman RB, Whiteside T, Sanzo K, Lee J, Kirkwood J. Perceived social support and tumor estrogen/progresterone receptor status as predictors of natural killer cell activity in breast cancer patients. Psychosom Med 1990;52:73-85.
30. Levy SM, Herberman RB, Lippman M, D'Angelo T, Lee J. Immunological and psychosocial predictors of disease recurrence in patients with early-stage breast cancer. Behav Med 1991;67-75.
31. Ottaway CA, Husband AJ. Central nervous system influences on lymphocyte migration. Brain Behav Immunol 1992;6:97-116.
32. Kavelaars A, Ballieux RE, Heijnen CJ. Differential effects of β-endorphin on cAMP levels in human peripheral blood mononuclear cells. Brain Behav Immunol 1990;4:171-179.
33. Paterson AG, Grimshaw AD, Webster DJT. The predictive values of T-lymphocyte counts in breast cancer patients treated by endocrine manipulation. Eur J Surg Oncol 1989;131-137.
34. Yonemoto RH, Schick P, Albano W, Fujisawa T, Waldman SR. Immune responses in the treatment of advanced carcinoma of the breast. Effects of adrenalectomy. Arch Surg 1977;112:991-996.
35. Labrie F, Poulin R, Simard J, Zhao HF, Labrie C, Dauvois S, Dumont M, Hatton AC, Poirier D, Merand Y. Interactions between estrogens, androgens, progestins, and glucocorticoids in ZR-75-1 human breast cancer cells. Ann NY Acad Sci 1990;575:130-148.
36. Moore JW, Thomas BS, Wang DY. Endocrine status and the epidemiology and clinical course of breast cancer. Cancer Surv 1986;3:537-559.
37. Baum M. Does surgery disseminate or accelerate cancer? Lancet 1996;347:260.
38. Berry J, Green BJ, Matheson DS. Modulation of natural killer cell activity by tamoxifen in stage I post-menopausal breast cancer. Eur J Cancer Clin Oncol 1987;23:517-520.
39. Tichatschek E, Zielinksi CC, Muller CH, Sevelda P, Kubista E, Czerwenka K, Spona J, Wolf H, Eibl MM. Long-term influence of adjuvant therapy on natural killer cell activity in breast cancer. Cancer Immunol Immunother 1988;27:278-282.
40. Brenner BG, Margolese RG. The relationship of chemotherapeutic and endocrine intervention on natural killer cell activity in human breast cancer. Cancer 1991;68:482-488.